• More septic patients should be able to return to day-to-day life sooner

    Sepsis is a disease growing in prevalence – early discovery and diagnostics will be key to its management

  • Hours instead of days

    Within 4 hours ASTrID® will identify the cause of sepsis and within an additional 6 hours, deliver the antibiotic susceptibility profile

  • Fighting antibiotic resistance

    The fully automated ASTar™ system will deliver phenotypic AST results in hours, enabling specific treatments to be administered quicker

Today’s time-consuming diagnostics of sepsis leads to an unnecessary amount of hospital days and an overuse of broad spectrum antibiotics. Q-linea´s fully automated solutions will enable healthcare providers to accurately diagnose sepsis in the shortest possible time. Our analysis platforms will drastically reduce the time for sepsis diagnosis.

ASTar™ will deliver answers about antibiotic susceptibility within six hours directly from positive blood cultures. The ASTrID® platform will identify the cause of sepsis directly from venous blood and deliver an antibiotic susceptibility profile in ten hours. Both systems will report true minimal inhibitory concentration values.

Detection direct from patient

Pathogen identification

Antibiotic susceptibility testing

Rapid AST directly from blood culture

ASTar™ is a fully automated instrument for Antibiotic Susceptibility Testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. ASTar shortens time to result, enabling early use of antibiotics specifically targeting the disease-causing pathogen. ASTar is currently under development and will be available in 2018 for research use only.

Read more about ASTar »

Sepsis diagnostics in hours instead of days

Sepsis is a disease growing in prevalence – early discovery and diagnostics will be key to its management. By using a technology that eliminates the need for traditional blood cultures the ASTrID® platform will shorten the current lead times in sepsis treatment by several days. The ASTrID platform is currently under development with the goal to start CE-IVD validation in 2020 followed by FDA certification shortly after.

Read more about ASTrID »

Meet us at ECCMID 2018 in Madrid

August 30

Booth no 47, April 21-24 in Feria de Madrid. Please join us at the meeting, and take the chance to talk to our representatives about or new system,… Read more

Read more

Poster presentation at ASM Microbe 2017

May 17

Q-linea will present a poster at ASM Microbe 2017, on Saturday Jun 3, 12:15 PM – 2:15 PM, poster board number: SATURDAY – 425. Abstract Title: Evaluation of a… Read more

Read more

New poster publication

April 7

Presented at Sepsis 2016, Dec 6-8, Paris. “Highly multiplexed molecular pathogen ID followed by phenotypic AST from whole blood using a novel fully automated system”. Find it here… Read more

Read more